Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy, PT Raised to $40

Symbols: BMRN
Share

Deutsche Bank has upgraded BioMarin Pharmaceuticals (NASDAQ: BMRN) from Hold to Buy and has raised the price target from $27 to $40.


 
 
< Previous
UBS Upgrades Holly Energy Partners
Next >
Citigroup Upgrades Auxilium Pharmaceuticals to Buy, PT Raised to $25
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust